» Articles » PMID: 26693516

Data in Support of a Functional Analysis of Splicing Mutations in the IDS Gene and the Use of Antisense Oligonucleotides to Exploit an Alternative Therapy for MPS II

Overview
Journal Data Brief
Date 2015 Dec 23
PMID 26693516
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

This data article contains insights into the methodology used for the analysis of three exonic mutations altering the splicing of the IDS gene: c.241C>T, c.257C>T and c.1122C>T. We have performed splicing assays for the wild-type and mutant minigenes corresponding to these substitutions. In addition, bioinformatic predictions of splicing regulatory sequence elements as well as RNA interference and overexpression experiments were conducted. The interpretation of these data and further extensive experiments into the analysis of these three mutations and also into the methodology applied to correct one of them can be found in "Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II" Matos et al. (2015) [1].

Citing Articles

Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.

Chen S, Heendeniya S, Le B, Rahimizadeh K, Rabiee N, Zahra Q BioDrugs. 2024; 38(2):177-203.

PMID: 38252341 PMC: 10912209. DOI: 10.1007/s40259-024-00644-7.


Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example.

Santos J, Goncalves M, Matos L, Moreira L, Carvalho S, Prata M Life (Basel). 2022; 12(5).

PMID: 35629276 PMC: 9146820. DOI: 10.3390/life12050608.


Opportunities and challenges for antisense oligonucleotide therapies.

Kuijper E, Bergsma A, Pijnappel W, Aartsma-Rus A J Inherit Metab Dis. 2020; 44(1):72-87.

PMID: 32391605 PMC: 7891411. DOI: 10.1002/jimd.12251.


Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.

Whiteman D, Kimura A Drug Des Devel Ther. 2017; 11:2467-2480.

PMID: 28860717 PMC: 5574592. DOI: 10.2147/DDDT.S139601.

References
1.
Cartegni L, Wang J, Zhu Z, Zhang M, Krainer A . ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003; 31(13):3568-71. PMC: 169022. DOI: 10.1093/nar/gkg616. View

2.
Stamm S, Riethoven J, Le Texier V, Gopalakrishnan C, Kumanduri V, Tang Y . ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res. 2005; 34(Database issue):D46-55. PMC: 1347394. DOI: 10.1093/nar/gkj031. View

3.
Smith P, Zhang C, Wang J, Chew S, Zhang M, Krainer A . An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet. 2006; 15(16):2490-508. DOI: 10.1093/hmg/ddl171. View

4.
Matos L, Goncalves V, Pinto E, Laranjeira F, Prata M, Jordan P . Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II. Biochim Biophys Acta. 2015; 1852(12):2712-21. DOI: 10.1016/j.bbadis.2015.09.011. View